More Data Needed To Assess Sinovac Jabs: Experts

"); jQuery("#212 h3").html("

Related News Programmes

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1570127_1_20210113184624.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1570127-20210113.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1570127-20210113.htm', 'DCS.dcsqry', '' ); } } }); }); });

2021-01-13 HKT 11:31

Share this story

facebook

  • Medical experts say the data available so far on the efficacy of the Sinovac coronavirus jabs must be interpreted carefully. File image: Shutterstock

    Medical experts say the data available so far on the efficacy of the Sinovac coronavirus jabs must be interpreted carefully. File image: Shutterstock

Medical experts on Wednesday said more data is needed to evaluate the efficacy of the coronavirus vaccine produced by mainland company Sinovac, in view of media reports that the jabs were found to be 50 percent effective during trials in Brazil.

Infectious disease specialist Joseph Tsang from Hong Kong Medical Association said the data released so far was preliminary and incomplete, and should be interpreted carefully.

"According to the media, the 50.4 per cent efficacy rate includes patients with mild symptoms and those asymptomatic carriers. So whether the asymptomatic carriers bring down the figures, we don't know at this point. So we have to get more data from Sinovac in order to interpret as a whole," he said.

Tsang said he also hoped to see more data collected from other countries which have used Sinovac vaccines, rather than just Brazil.

A specialist in respiratory medicine, Dr Leung Chi-chiu, said the figures available currently cannot be used to make apple-to-apple comparisons between coronavirus vaccines produced by different companies.

"We are not certain what these figures are talking about. There are multiple levels of efficacy. We can talk about efficacy against all infections. We can talk about efficacy against symptomatic infections. We can talk about efficacy against serious infections. All these have different meanings," he said.

"We need to look at the full data set before we can have a better guess of the actual situation and compare the efficacy between different vaccines," Leung said.

The Secretary for the Civil Service, Patrick Nip, meanwhile, said an expert panel appointed by the government would meet this week and review relevant clinical data.

Nip, who is one of the officials in charge of the vaccination programme to be rolled out in Hong Kong, said the panel would give clear advice on the matter later.

It is expected that Hong Kong people will start receiving coronavirus vaccinations in mid-February, with jabs produced by Sinovac being the first to arrive in the city.

RECENT NEWS

Ping An P&C And FAW Hongqi Launch Hongqi Intelligent Driving Protection Services

Ping An Property & Casualty Insurance Company of China (Ping An P&C), a subsidiary of Ping An Insurance, has pa... Read more

HKSTP European Innovation Mixer Tour Nurtures Global Ties For Hong Kong

The Hong Kong Science and Technology Parks Corporation (HKSTP), led by CEO Albert Wong, conducted the HKSTP European In... Read more

The Full List Of Fintech Unicorns In Hong Kong (2025)

Hong Kong’s fintech landscape has evolved into a dynamic force in Asia, driven by regulatory innovation, technologica... Read more

HKSTPs EPIC 2025 Competition Returns, Doubling Investment Pool To US$100M

The 9th edition of the Elevator Pitch International Competition, also known as the EPIC 2025 competition, officially op... Read more

RedotPay Secures $40 Million Series A Funding, To Advance Global Crypto Payment Solutions

RedotPay secures $40 million Series A funding, marking a major milestone for the crypto payment platform. The announcem... Read more

BOOM Hits $2 Billion In AUM, Reinvesting Into Crypto And Tokenised Securities

BOOM, a Hong Kong-based online investing platform for high-net-worth individuals, announced on 12 March 2025 that it ex... Read more